Alnylam Pharmaceuticals, the Cambridge, MA-based biotech developing drugs using RNA interference technology, said today it made a $5 million investment in Vancouver-based Tekmira Pharmaceuticals in order to gain access to its delivery technologies. The deals gives Alnylam expanded rights to intellectual property held by Protiva Biotherapeutics before it merged with Tekmira, and to new intellectual property created by the combined company, Alnylam said in a statement.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
